Olimel N7e (Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin)

The formulation provides the building blocks needed for ribosomal protein synthesis. By delivering valine, leucine, isoleucine and other essential amino acids, it activates the mTOR pathway, promotes muscle protein accretion, restores nitrogen balance, and aids tissue repair during periods of increased metabolic demand.

The prescribed dose of Olimel N7e is determined by the treating clinician based on the patient’s age, weight, clinical condition, and nutritional requirements. Healthcare professionals calculate the appropriate amount and frequency to achieve the desired therapeutic effect.

Olimel N7e should only be used in pregnancy or while breastfeeding if the prescriber judges that the potential benefit outweighs any possible risk to the fetus or infant. Limited data are available, so careful clinical assessment is essential before initiating therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and the necessary import documentation.

Unlike generic protein powders that contain a mixture of proteins, Olimel N7e delivers a precise profile of free essential amino acids, allowing faster absorption and more direct stimulation of the mTOR pathway. This can be advantageous in clinical settings where rapid nitrogen delivery and specific amino‑acid ratios are needed.

Olimel N7e should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the powder from moisture, direct sunlight, and extreme heat to maintain stability and potency throughout its shelf life.

The product is supplied as a powdered formulation intended for oral use. It is typically reconstituted with water or mixed into a suitable beverage according to the prescriber’s instructions, and then ingested promptly to ensure optimal absorption.

The most serious risks include allergic reactions that may progress to anaphylaxis, metabolic acidosis in susceptible patients, and rare occurrences of hyperuricemia or hyperammonemia, particularly in individuals with severe renal or hepatic impairment. Immediate medical attention is required if any of these events occur.

Olimel N7e is contraindicated in patients with known hypersensitivity to any of its amino‑acid components, in those with severe renal or hepatic failure, and in individuals with inborn errors of metabolism affecting the supplied amino acids. Clinicians should also avoid use in patients receiving high‑dose protein supplements without proper monitoring.